undamentalytics Newsletter
Sign in

Regenxbio Inc. revenue

Regenxbio Inc.'s revenue was $170m in fiscal 2025, up 104.5% on the year before. Since fiscal 2013 ($6.1m) it has grown at a compound 32.0% a year. Over the last twelve months it was $174m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue668510219351554701139083170174
Growth on the year before—+0.5%+24.0%−39.5%+126.5%+>999%−83.9%+338.7%+204.3%−76.0%−19.9%−7.7%+104.5%—
Gross profit————920927119419585350——
Gross margin————83.6%95.6%76.6%76.9%89.0%51.6%58.8%59.7%——

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Licenses and services $156M ▲ 90.7%
Zolgensma and Itvisma Royalties $83.2M ▲ 2.1%
Zolgensma Royalties $82.5M ▲ 1.3%
Nippon Shinyaku Licenses $72.9M —
Services $14.2M ▲ 936.1%
Total Service Revenue $14.2M ▲ 936.1%
Nippon Shinyaku Services $11.8M —
Other Service Revenue $2.4M ▲ 71.9%
Itvisma Royalties $641,000 —

These categories overlap or exclude eliminations, so shares aren't shown.

From Regenxbio Inc.'s 10-K filed March 5, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Regenxbio Inc. $174m 12.0% 21.6%
Nuvation Bio Inc. $170m 1083.6% —
Arbutus Biopharma Corp $182m 1078.8% 97.6%
Immunitybio, Inc. $166m 192.9% 554.3%
Urogen Pharma Ltd. $189m 100.3% 37.6%
Beam Therapeutics Inc. $156m 158.9% 24.9%

Compare with peers

Head to head: NUVB vs RGNXABUS vs RGNXIBRX vs RGNX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Regenxbio Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Regenxbio Inc.